Clinical Trial Update: A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the pharmacokinetics and safety of dupilumab in children aged 6 months to under 18 years with prurigo nodularis; the trial is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Sanofi | Conditions: Prurigo Nodularis | Phase 3 | Status: RECRUITING